Precision-engineered exosome therapeutics for disease-specific intervention. Leveraging our targeted delivery platform to treat oncology, autoimmune, and rare diseases with unmatched specificity.
Our proprietary surface engineering platform equips exosomes with disease-specific targeting ligands, achieving precise tissue and cell-type selectivity.
Ligand-Receptor Mediated
Engineered surface ligands bind specifically to overexpressed receptors on diseased cells, achieving >90% targeting accuracy in validated models. Each indication uses a unique ligand cocktail optimized through high-throughput screening.
Therapeutic Payload
Proprietary electroporation and incubation methods achieve high-efficiency loading of siRNA, mRNA, CRISPR components, or small molecule drugs with >80% encapsulation efficiency and preserved biological activity.
In Vivo Tracking
Near-infrared fluorescence and bioluminescence imaging confirm targeted accumulation at disease sites with minimal off-tissue distribution, typically achieving 15-25x enrichment at target vs. healthy tissue.
PK/PD Modeling
Population pharmacokinetic modeling guides dose selection and treatment frequency, maximizing therapeutic index while minimizing potential adverse effects across diverse patient populations.
Targeted exosomes delivering immune checkpoint modulators to tumor-associated macrophages. IND-enabling studies completed. Phase I preparation underway.
Exosomes engineered to deliver antigen-specific tolerance signals in rheumatoid arthritis and lupus models. Preclinical validation showing 70%+ disease activity reduction.
BBB-penetrant exosomes delivering neuroprotective cargo for Alzheimer's disease. Demonstrated 45% reduction in amyloid plaque burden in transgenic mouse models.
Gene-correcting exosomes for monogenic diseases. Proof of concept demonstrated in Duchenne muscular dystrophy cell models with restored dystrophin expression.
Our clinical research network spans 9 top-tier hospitals across China, providing access to diverse patient populations and world-class clinical research infrastructure.
Join us in advancing targeted exosome therapeutics from bench to bedside.
Partner With Us